Anaptysbio Inc

Delaware Chancery Court Rules in Favor of Anaptys by Dismissing Tesaro’s Anticipatory Breach Claim

Anaptys Completes Separation of First Tracks Biotherapeutics and Now Exclusively Manages GSK and Vanda Financial Collaborations

Anaptys Announces $100 Million Stock Repurchase Plan and Provides a Business Update

First Tracks Biotherapeutics, the Planned Spin-Off of Anaptys, Secures Commitments of $145 Million in Private Placement

Anaptys Board of Directors Approves Spin-Off of First Tracks Biotherapeutics